Jefferies Financial Group Inc. Buys New Position in Inspire Medical Systems, Inc. $INSP

Jefferies Financial Group Inc. bought a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 307,588 shares of the company’s stock, valued at approximately $28,369,000.

Other large investors have also bought and sold shares of the company. CWM LLC boosted its stake in Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after buying an additional 242 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at $40,000. Daiwa Securities Group Inc. boosted its position in shares of Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 130 shares during the period. Larson Financial Group LLC boosted its position in shares of Inspire Medical Systems by 21,266.7% in the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after purchasing an additional 638 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Inspire Medical Systems in the 3rd quarter valued at $49,000. Institutional investors own 94.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Piper Sandler lowered Inspire Medical Systems from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $85.00 to $55.00 in a research report on Tuesday, May 5th. Mizuho decreased their price target on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Truist Financial decreased their price target on Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating for the company in a research report on Tuesday, May 5th. Evercore set a $55.00 price target on Inspire Medical Systems in a research report on Tuesday, May 5th. Finally, Morgan Stanley set a $60.00 price target on Inspire Medical Systems in a research report on Wednesday, February 18th. Four equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $81.84.

Inspire Medical Systems Trading Down 2.1%

Shares of Inspire Medical Systems stock opened at $43.79 on Friday. The stock has a 50-day moving average price of $51.61 and a 200 day moving average price of $76.29. The company has a market cap of $1.26 billion, a P/E ratio of 9.75, a P/E/G ratio of 4.53 and a beta of 0.83. Inspire Medical Systems, Inc. has a 1 year low of $39.61 and a 1 year high of $147.66.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.38. The firm had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The business’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, equities analysts forecast that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.